DexCom (DXCM): Growth Broadens, but Valuation Limits Upside
DexCom posted 13% Q2 revenue growth, 46% EPS growth, and raised 2026 guidance, but the stock still screens as a Hold at a rich valuation. The report highlights expanding reimbursement, strong G7 15 Day adoption, and a growing opportunity in non-insulin type 2 diabetes.
DexCom (DXCM) is a high-quality growth story earning an overall grade of B+, but it is only a Hold right now. The company’s improving margins, broadening reimbursement, and expanding opportunity in non-insulin type 2 diabetes support the thesis, yet the shares already discount a lot of that progress. Our fair value is $86.
Thesis
DexCom (DXCM) combines a strong recurring-revenue medical device model with improving margins, broadening reimbursement, and a growing opportunity beyond insulin-treated diabetes. The investment case rests on three facts: Q2 2026 revenue rose 13% to $1.31B, non-GAAP diluted EPS increased 46% to $0.70, and management raised full-year 2026 revenue guidance to $5.18B-$5.25B.
The growth engine is becoming broader. U.S. revenue increased 11% in Q2, international revenue rose 19% on a reported basis, and the CONNECT randomized trial produced a 0.9 percentage-point A1C improvement versus the control group among people with type 2 diabetes who do not use insulin. DexCom also reported 97% median wear in the 26-week study, giving physicians and payers evidence that patients will use the technology consistently.
The main restraint is valuation. DXCM trades at 34.0x trailing earnings, 28.2x forward earnings, and 6.6x enterprise value to revenue. Those are demanding figures, even with a 5.96% free-cash-flow yield and a PEG ratio of 1.3. For a moderate-risk investor, the result is a Hold: a high-quality compounder, but not a bargain at $81.13.
Company Overview
DexCom is a San Diego-based medical device company founded in 1999 and listed on Nasdaq under DXCM. It designs, develops, and commercializes continuous glucose monitoring systems for diabetes management and metabolic health. The company had approximately 11,000 employees and generated $4.66B of fiscal 2025 revenue.
Its product portfolio includes Dexcom G7, G7 15 Day, G6, Dexcom ONE+, Dexcom Share, Dexcom Follow, and Stelo. G7 and G7 15 Day serve the core prescription CGM market, while Stelo addresses adults with prediabetes and type 2 diabetes who do not use insulin. That portfolio gives DXCM exposure to both the established diabetes market and earlier-stage metabolic health.
▌Common Questions
Frequently asked questions
+Is DXCM stock a buy right now?
DexCom is not a Buy right now; it is a Hold. The business is executing well with 13% revenue growth, 46% EPS growth, and improving reimbursement, but the valuation is still demanding enough to limit near-term upside.
+What is DXCM's fair value?
DexCom's fair value is $86. We arrive at that view by weighing its 34.0x trailing earnings, 28.2x forward earnings, and 6.6x EV/revenue against strong margin expansion, a 5.96% free-cash-flow yield, and the growing adoption of G7 15 Day and non-insulin type 2 use cases.
+Why did DexCom keep a Hold rating despite strong growth?
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
The business is built around recurring sensor use rather than one-time equipment sales. DexCom markets through endocrinologists, physicians, diabetes educators, payers, and direct or retail channels. Its $4.97B trailing revenue base, 20.1% net margin, and $1.80B of free cash flow show the economic scale already attached to the platform.
Business Segment Deep Dive
DexCom's disclosed operating view emphasizes geography rather than separately named product profit centers. The United States produced $933M of Q2 2026 revenue, or 71% of the total, while international markets generated $375M, or 29%.
The U.S. remains the earnings anchor, but international growth is faster. U.S. revenue increased 11% year over year, while international revenue grew 19% reported and 16% organically. France and Canada were highlighted as strong markets following reimbursement expansion, and DexCom launched DexCom Flex in Germany for selected type 2 populations.
The mix matters because international growth can extend the company's runway while U.S. adoption matures. At the same time, the U.S. still contains approximately 9 million people with CGM coverage who are not using a CGM, giving DXCM a substantial conversion opportunity before additional coverage expansion.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship product is the G7 platform, with G7 15 Day becoming the most important current upgrade cycle. The 15-day system extends wear time, improves customer convenience, and is integrated with Tandem pump users, including Mobi. DexCom said G7 15 Day was accessible to all adult G7 customers in the U.S. after the latest integration expansion.
Management expects nearly 50% of the U.S. customer base to convert to G7 15 Day by the end of 2026. The product is also supporting gross-margin expansion, while G7 net promoter scores increased in each of the last three quarters. That combination of longer wear, stronger satisfaction, and improving economics is more valuable than a simple product refresh.
Stelo is the other strategic product. Its redesigned app launched with AI-driven insights and enhanced food logging, creating a more consumer-oriented experience. Stelo's contribution began building in 2025, and management plans international expansion into markets including the United Kingdom, Australia, New Zealand, and South Korea.
Innovation & Competitive Advantage
DexCom's strongest advantage is the combination of clinical evidence, product familiarity, and a large installed base. In CGM, accuracy matters, but so do comfort, alerts, connectivity, reliability, and the willingness of patients to wear the device continuously. The CONNECT trial strengthens the clinical case for use among non-insulin type 2 patients.
DexCom is also building a software and data layer. Smart Basal is designed to help patients and physicians optimize basal insulin dosing. In pilot practices, management said the module helped patients reach an optimal basal dose in three weeks on average, compared with 12 weeks or longer in routine care.
The FDA's selection of DexCom as the first participant in the TEMPO digital health device pilot adds regulatory visibility. The program gives DXCM a framework to advance glucose-health and prediabetes screening technologies. The opportunity is meaningful, but the investment case still depends on converting clinical evidence into reimbursement and recurring use.
Operations & Supply Chain
Operations improved sharply in Q2 2026. Non-GAAP gross margin reached 64.1%, up from 60.1% in Q2 2025, helped by manufacturing efficiencies, quality-management gains, optimized shipping patterns, and the early mix benefit from G7 15 Day.
DexCom is expanding production capacity in Ireland, with commercial production expected later in 2026. The company also operates a manufacturing facility in Arizona, where it held its 2026 Investor Day. Investing in capacity while raising operating-margin guidance to 23.5%-24.0% shows that current scale is absorbing much of the incremental spending.
The supply chain still carries device-industry risks. DexCom's 2025 10-K identifies reliance on third-party suppliers and single-source components for some critical parts. The company also faces exposure to freight costs, fuel prices, quality control, and production interruptions. Q2 execution was strong, but the operational moat must be maintained as international volume and product complexity increase.
Market Analysis
The relevant market is continuous glucose monitoring, not the broad medical-device market alone. DexCom's expansion targets people with type 2 diabetes who do not use insulin, prediabetes patients, and consumers seeking metabolic-health insights. Management cited 25 million U.S. type 2 diabetes patients who do not use insulin and 115 million Americans with prediabetes.
Reimbursement is the market's main gatekeeper. As of summer 2026, DexCom said all four largest commercial pharmacy benefit managers covered people with diabetes, representing reimbursement for more than 7 million type 2 patients who do not use insulin. That creates a bridge between clinical evidence and commercial adoption.
The company also identified approximately 9 million U.S. people who already have CGM coverage but are not using the technology. This is a more immediate market opportunity than relying only on new reimbursement decisions. The long-term addressable market expands further if CGM becomes part of metabolic-health monitoring rather than remaining limited to diabetes treatment.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
DXCM serves several connected customer groups. Patients use the sensors and apps; physicians and diabetes educators prescribe or recommend them; payers determine coverage; and pump manufacturers depend on interoperability with CGM systems. A product that satisfies only one of these groups will struggle, while G7 15 Day is designed to address all four.
The CONNECT study provides useful evidence about patient engagement. Participants achieved 97% median wear over 26 weeks, spent more than five additional hours per day in the normal glucose range compared with the control group, and recorded a 1.6% A1C improvement from baseline. Those figures support the argument that CGM can generate measurable outcomes rather than simply more data.
The customer base is also becoming more consumer-oriented. Stelo's food logging, AI-driven insights, and nutrition-focused connection with Nutrisense target users who may not begin with an intensive diabetes-management need. Management said Nutrisense's incremental top-line contribution would be measured in millions for 2026, making its strategic value more important than its immediate revenue.
Competitive Landscape
Abbott (ABT) is DexCom's primary direct competitor through the FreeStyle Libre platform. Medtronic (MDT) competes through Guardian Connect and Simplera products, especially where CGM is integrated with insulin pumps. Senseonics (SENS) offers an implantable CGM model, while Roche Diabetes Care, Ascensia Diabetes Care, and LifeScan remain relevant in broader glucose monitoring.
Competition centers on accuracy, wear time, comfort, ease of use, price, reimbursement, clinician acceptance, distribution, and pump connectivity. DexCom's G7 15 Day improves its position on wear time and the company has a strong brand in prescription CGM. Abbott's scale and pricing position remain serious competitive forces.
The competitive field is widening beyond traditional medical-device companies. DexCom's 2025 10-K flags general wellness wearables, China-based entrants, and other digital-health companies as potential sources of pressure. GLP-1 therapies also influence the market, although the CONNECT results support management's view that CGM and incretin therapy can be complementary.
Macro & Geopolitical Landscape
The strongest macro forces for DXCM are chronic disease prevalence, healthcare access, remote monitoring, and the shift toward home-based care. These are visible in the company's expanding reimbursement footprint and its focus on digital insights. The product's recurring nature also gives DexCom a more durable revenue structure than a one-time equipment supplier.
Foreign exchange remains a measurable pressure on international results. Management estimated a $15M impact to second-half international revenue from recent currency movements relative to prior guidance. Fuel prices also affected shipping economics, although optimized shipping patterns helped protect Q2 execution.
Regulation is both a barrier and a moat. The FDA's Quality Management System Regulation became effective on February 2, 2026, increasing the importance of documented quality systems. FDA oversight of AI-enabled medical devices is also evolving, which matters for Stelo and Smart Basal. DexCom's clinical evidence and regulatory experience give it an advantage, but compliance costs and reimbursement decisions remain central risks.
Balance Sheet Health
▌Premium Members Only
DexCom ended the quarter with $1.80B of free cash flow and a 20.1% net margin, underscoring a balance sheet supported by recurring sensor revenue and strong cash generation.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Q2 revenue rose 13% to $1.31B while non-GAAP diluted EPS jumped 46% to $0.70, showing that DexCom’s growth is now translating into faster earnings expansion.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Management lifted full-year 2026 revenue guidance to $5.18B-$5.25B after a quarter in which U.S. revenue grew 11% and international revenue climbed 19% reported.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
DexCom trades at 34.0x trailing earnings, 28.2x forward earnings, and 6.6x EV/revenue, a premium that keeps the valuation grade at B despite a 5.96% free-cash-flow yield.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
At $81.13, DexCom sits below our $86 fair value, with the report’s price framework implying more upside only if growth and margin gains continue to compound.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
DexCom is executing from a position of strength. Q2 2026 delivered $1.31B of revenue, 64.1% non-GAAP gross margin, $421M of adjusted EBITDA, and $0.70 of non-GAAP diluted EPS. The company is expanding its product reach at the same time that manufacturing efficiency and operating leverage are improving.
The stock is therefore a Hold rather than a Sell. The clinical evidence, reimbursement progress, net cash, and recurring sensor model support long-term value creation. But at $81.13 and 28.2x forward earnings, the market is already paying for much of that progress. For a moderate-risk portfolio, DXCM is best treated as a high-quality business that becomes substantially more attractive at a lower entry price.
DexCom kept a Hold because the operating story is strong but the stock already prices in a lot of success. Q2 revenue rose to $1.31B, gross margin reached 64.1%, and management raised 2026 guidance, yet the shares still trade at a premium multiple.
+What is driving DexCom's growth?
Growth is being driven by broader reimbursement, stronger U.S. and international adoption, and the G7 15 Day upgrade cycle. The report also points to the CONNECT trial and Stelo as catalysts for expanding use beyond insulin-treated diabetes.
+How strong is DexCom's profitability?
DexCom's profitability is improving quickly, with non-GAAP gross margin at 64.1% and non-GAAP diluted EPS up 46% year over year to $0.70. The company also generated $1.80B of free cash flow and posted a 20.1% net margin, which supports the quality of the earnings base.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.